
SI Group to Acquire Assets from Albemarle
SI Group agrees to purchase certain Albemarle assets and products.
The acquisition will include Albemarle’s antioxidant product lines, as well as the Ibuprofen and Propofol businesses. In addition, applications and technical support capabilities in Shanghai and Baton Rouge, Louisiana will be included in the transaction. Subject to the required regulatory approvals, this acquisition is expected to be completed later this year.
Source:
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





